BR0209785A - Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente - Google Patents
Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um pacienteInfo
- Publication number
- BR0209785A BR0209785A BR0209785-0A BR0209785A BR0209785A BR 0209785 A BR0209785 A BR 0209785A BR 0209785 A BR0209785 A BR 0209785A BR 0209785 A BR0209785 A BR 0209785A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- solvates
- pharmaceutically acceptable
- esters
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
"COMPOSTO E SEUS SAIS, SOLVATOS E éSTERES HIDROLISáVEIS FARMACEUTICAMENTE ACEITáVEIS, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, MéTODO DE TRATAMENTO DE UMA DOENçA OU CONDIçãO MEDIADA POR HPPAR ALFA EM UM PACIENTE". Um composto de fórmula (I) e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis de fórmula I, em que X~ 1~ representa O ou S; R^ 1^ e R^ 2^ são independentemente H ou alquila C~ 1~ a C~ 3~ ou R^ 1^ e R^ 2^ que são ligados ao mesmo átomo de carbono podem juntos com o átomo de carbono ao qual eles são ligados formar um anel cicloalquila de 3-5 membros, R^ 3^ e R^ 4^ independentemente representam H, halogênio, CH~ 3~ e OCH~ 3~, R^ 5^ representa H ou alquila C~ 1~ a C~ 6~, X~ x~ representa NH, NCH~ 3~, ou O; um dentre Y e Z é N, e o outro é O ou S; R^ 6^ representa fenila ou piridila (em que N está em posição 2 ou 3) e é opcionalmente substituído por um ou mais halogênio, CF~ 3~, alquila C ~ 1 a 6~ reta ou ramificada (opcionalmente substituída por halogênio) com a condição que quando R^ 6^ é piridila, o N não é substituído.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0113231.5A GB0113231D0 (en) | 2001-05-31 | 2001-05-31 | Chemical compounds |
PCT/EP2002/005886 WO2002096895A1 (en) | 2001-05-31 | 2002-05-29 | Oxazol/ thiazol-derivatives activators of the hppar-alpha receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209785A true BR0209785A (pt) | 2004-06-01 |
Family
ID=9915636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209785-0A BR0209785A (pt) | 2001-05-31 | 2002-05-29 | Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente |
Country Status (29)
Country | Link |
---|---|
US (1) | US7157479B2 (pt) |
EP (1) | EP1399430B1 (pt) |
JP (1) | JP2004532267A (pt) |
KR (1) | KR100859591B1 (pt) |
CN (1) | CN1307166C (pt) |
AR (1) | AR034051A1 (pt) |
AU (1) | AU2002317765B2 (pt) |
BR (1) | BR0209785A (pt) |
CA (1) | CA2448205A1 (pt) |
CO (1) | CO5540297A2 (pt) |
CY (1) | CY1107206T1 (pt) |
CZ (1) | CZ20033252A3 (pt) |
DE (1) | DE60223805T2 (pt) |
DK (1) | DK1399430T3 (pt) |
ES (1) | ES2296965T3 (pt) |
GB (1) | GB0113231D0 (pt) |
HK (1) | HK1064367A1 (pt) |
HU (1) | HUP0400043A3 (pt) |
IL (1) | IL158929A0 (pt) |
MX (1) | MXPA03011032A (pt) |
MY (1) | MY132656A (pt) |
NO (1) | NO20035209L (pt) |
NZ (1) | NZ529754A (pt) |
PL (1) | PL367248A1 (pt) |
PT (1) | PT1399430E (pt) |
SI (1) | SI1399430T1 (pt) |
TW (1) | TWI245760B (pt) |
WO (1) | WO2002096895A1 (pt) |
ZA (1) | ZA200309095B (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1445258T3 (da) * | 2001-10-12 | 2009-10-12 | Nippon Chemiphar Co | Aktivator for peroxisomproliferator-aktiveret receptor delta |
US7553867B2 (en) | 2002-09-06 | 2009-06-30 | Takeda Pharmaceutical Company Limited | Furan or thiophene derivative and medicinal use thereof |
GB0314370D0 (en) * | 2003-06-19 | 2003-07-23 | Glaxo Group Ltd | Chemical compounds |
GB0323702D0 (en) * | 2003-10-09 | 2003-11-12 | Smithkline Beecham Corp | Chemical compound |
BRPI0416283A (pt) | 2003-11-05 | 2007-01-23 | Hoffmann La Roche | compostos, processo para a fabricação de compostos, composição farmacêutica, método para o tratamento e/ou prevenção de doenças que são moduladas por agonistas de ppar(delta) e/ou ppar(alfa) e uso destes compostos |
FR2882359A1 (fr) * | 2005-02-24 | 2006-08-25 | Negma Lerads Soc Par Actions S | Derives activateurs de ppar, procede de preparation et application en therapeutique |
CN101007790B (zh) * | 2006-01-27 | 2011-03-30 | 北京摩力克科技有限公司 | 草氨酸衍生物、其制备方法和医药用途 |
FR2901792A1 (fr) * | 2006-06-06 | 2007-12-07 | Negma Lerads Soc Par Actions S | DERIVES ACTIVATEURS DE PPARs, PROCEDE DE PREPARATION ET APPLICATION EN THERAPEUTIQUE |
EP2380884B1 (en) * | 2008-12-01 | 2014-02-12 | Mitsubishi Tanabe Pharma Corporation | Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof |
CN110803996B (zh) * | 2019-11-13 | 2022-01-11 | 台州市创源工业技术有限公司 | 一种羟基苄胺的合成方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000068151A (ko) * | 1996-08-19 | 2000-11-25 | 미즈노 마사루 | 프로피온산 유도체 및 그의 용도 |
KR100620337B1 (ko) * | 1998-03-10 | 2006-09-13 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 |
IL145923A0 (en) * | 1999-04-28 | 2002-07-25 | Aventis Pharma Gmbh | Tri-aryl acid derivatives as ppar receptor ligands |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
GB0113233D0 (en) * | 2001-05-31 | 2001-07-25 | Glaxo Group Ltd | Chemical compounds |
-
2001
- 2001-05-31 GB GBGB0113231.5A patent/GB0113231D0/en not_active Ceased
-
2002
- 2002-05-29 PT PT02747331T patent/PT1399430E/pt unknown
- 2002-05-29 WO PCT/EP2002/005886 patent/WO2002096895A1/en active IP Right Grant
- 2002-05-29 ES ES02747331T patent/ES2296965T3/es not_active Expired - Lifetime
- 2002-05-29 IL IL15892902A patent/IL158929A0/xx unknown
- 2002-05-29 SI SI200230654T patent/SI1399430T1/sl unknown
- 2002-05-29 AR ARP020101999A patent/AR034051A1/es unknown
- 2002-05-29 MX MXPA03011032A patent/MXPA03011032A/es active IP Right Grant
- 2002-05-29 DE DE60223805T patent/DE60223805T2/de not_active Expired - Fee Related
- 2002-05-29 TW TW091111392A patent/TWI245760B/zh not_active IP Right Cessation
- 2002-05-29 DK DK02747331T patent/DK1399430T3/da active
- 2002-05-29 BR BR0209785-0A patent/BR0209785A/pt not_active IP Right Cessation
- 2002-05-29 HU HU0400043A patent/HUP0400043A3/hu unknown
- 2002-05-29 CA CA002448205A patent/CA2448205A1/en not_active Abandoned
- 2002-05-29 CZ CZ20033252A patent/CZ20033252A3/cs unknown
- 2002-05-29 KR KR1020037015678A patent/KR100859591B1/ko not_active IP Right Cessation
- 2002-05-29 AU AU2002317765A patent/AU2002317765B2/en not_active Ceased
- 2002-05-29 EP EP02747331A patent/EP1399430B1/en not_active Expired - Lifetime
- 2002-05-29 NZ NZ529754A patent/NZ529754A/en unknown
- 2002-05-29 PL PL02367248A patent/PL367248A1/xx not_active Application Discontinuation
- 2002-05-29 US US10/478,936 patent/US7157479B2/en not_active Expired - Fee Related
- 2002-05-29 MY MYPI20021973A patent/MY132656A/en unknown
- 2002-05-29 JP JP2003500074A patent/JP2004532267A/ja active Pending
- 2002-05-29 CN CNB028149424A patent/CN1307166C/zh not_active Expired - Fee Related
-
2003
- 2003-11-21 ZA ZA200309095A patent/ZA200309095B/en unknown
- 2003-11-24 NO NO20035209A patent/NO20035209L/no not_active Application Discontinuation
- 2003-12-03 CO CO03106490A patent/CO5540297A2/es not_active Application Discontinuation
-
2004
- 2004-09-13 HK HK04106944A patent/HK1064367A1/xx not_active IP Right Cessation
-
2008
- 2008-02-19 CY CY20081100202T patent/CY1107206T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0210077A (pt) | Composto, seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa | |
ATE396988T1 (de) | Chinolin- und chianzolinderivate zur behandlung von tumoren | |
CY1107168T1 (el) | Παραγωγα φαινυλοαλκανοϊκου οξεος και φαινυλοξυαλκανοϊκου οξεος ως ενεργοποιηται hppar | |
TW200510441A (en) | Novel compounds | |
WO2008005519A3 (en) | Novel pyridazine compound and use thereof | |
DE60009511D1 (de) | Nematizide trifluorbutene | |
TR200302242T2 (tr) | Protein kinaz önleyicileri olarak pirolopirimidinler | |
IT1311922B1 (it) | Composti farmaceutici. | |
HK1072770A1 (en) | Bicyclic compound | |
DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
BR0209785A (pt) | Composto e seus sais, solvatos e ésteres hidrolisáveis farmaceuticamente aceitáveis, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar alfa em um paciente | |
NO20051282L (no) | Antitumorale analoger av lamellariner. | |
ATE453389T1 (de) | Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen | |
NO972887L (no) | Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel | |
DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
DE60126864D1 (de) | Verfahren zur Herstellung von (E,Z) 3-(2-aminoethoxyimino)-androstane-6,17-dione und Analoge | |
DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
DE60224884D1 (de) | Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen | |
NZ221314A (en) | 1,4-dihydropyridine derivatives and pharmaceutical composition | |
ATE145911T1 (de) | Inositol-phosphat-analog als kalzium- antagonistische substanz | |
ATE399018T1 (de) | Verwendung von s-ä2,3-bispalmitoyloxy-(2rs)- propylücysteinyl-gnndesnisfkek (malp-2) | |
BR0302137A (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma condição ou doença mediada por hppar em um paciente | |
UA96296C2 (en) | Pyridazine compounds and use thereof | |
NO20010332D0 (no) | Nye 6-deoksyerytromycinderivater, metoder for fremstilling av disse, og anvendelse som medisiner | |
CY1105981T1 (el) | Ενωσεις 5-πυριδυλ-1,3-αζολιου, μεθοδοι παρασκευης αυτων και χρηση αυτων |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INTE.CL: C07D 277/56, A61K 31/42, A61K 31/425 Ipc: C07D 277/56 (2011.01), A61K 31/42 (2011.01), A61K |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |